O2‐03‐05: Beta‐amyloid‐17 is a major beta‐amyloid fragment isoform in cerebrospinal fluid and blood that shows diagnostic value

Pérez, Virginia; Sarasa, Leticia; Allué, José Antonio; Casabona, Diego; Montañés, María; Insua, Daniel; Badi, Hassnae; Monleón, Inmaculada; Lacosta, Ana M.; Josè, Itziar San; Tárraga, Lluís; Boada-Rovira, Mercè; Pesini, Pedro; Sarasa, Manuel

doi:10.1016/j.jalz.2012.05.638

Cited by 10 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perez et al (Pérez et al, 2012) found that significant variation in the ratio of free and cell-bound Aβ42 levels in the blood of mild cognitive impairment patients versus age-matched control groups. This indicates the plasma level of Aβ is a precise and accurate biomarker for the diagnosis of AD.…”

Section: Amyloid Markersmentioning

confidence: 99%

Alzheimer’s Disease: Biomarkers And Future Targets For Drug Intervention

Paul

Balasubramanian

Ramalingam

2020

ijrps

View full text Add to dashboard Cite

Alzheimer’s disease is a progressive disorder and the most common types of dementia that develops in the elderly, characterised by gradual memory loss and cognitive skills of an individual. The neurodegenerative disease is characterised by intracellular settling of hyperphosphorylated tau protein like neurofibrillary tangles (NFT) in the neuronal cytoplasm and extracellular settling of beta-amyloid peptide(Aβ). These changes lead to cognitive decline due to the loss of synapses and neurons involved in learning, memory and cognitive function. Amyloid precursor protein, presenilin 1, presenilin 2 and TREM2 are some of the genes involved in the development of the disease. The current treatment for AD is the cholinesterase inhibitors such as donepezil, galantamine, rivastigmine, and N-methyl D- aspartate antagonist memantine. Other recommended adjuvant therapy was vitamin D, omega-3 fatty acid, Mediterranean diet, and aerobic exercise. Diagnosis is based upon clinical presentation and imaging biomarkers. This review summarises AD biomarkers such as cerebrospinal fluid biomarkers, circulatory biomarkers, inflammatory markers and oxidative biomarkers which are under study and the future targets of drug intervention. The amyloid-beta peptide, tau protein, and β-secretase may be the possible sites of drug action in the future.

show abstract

Section: Amyloid Markersmentioning

confidence: 99%

Alzheimer’s Disease: Biomarkers And Future Targets For Drug Intervention

Paul

Balasubramanian

Ramalingam

2020

ijrps

View full text Add to dashboard Cite

show abstract

“…The failure to replicate findings is the biggest obstacle in establishing credibility of blood-based biomarkers [2]. Biomarkers like Amyloid-β (Aβ), the ratio of Aβ1-42 to Aβ1-40 [3], and Aβ1-17 Perez, et al [4]have been found to have potential of becoming good predictors of MCI and AD. The lack of statistical reproducibility of results across different cohorts may be attributed to factors like age, underlying cognitive health of subjects Toledo et al [5], the diet of the subjects and other between subjects variability.…”

Section: Literature Review and Study Prospectsmentioning

confidence: 99%

Untitled

2018

BBOAJ

View full text Add to dashboard Cite

Finding potent and clinically standardized biomarkers is of utmost importance for early detection of any disease which further helps in developing prevention and cure techniques. Use of statistical techniques becomes inevitable to validate the predictive power of the biomarkers and also to ensure the reproducibility of results. Identification of statistically significant covariates and competing risks is another important aspect of any biostatistical study for understanding disease progression. This paper attempts to review some useful statistical and biostatistical techniques being utilized in the study of dementia, Alzheimer's disease (AD) in particular, and also proposes some potentially reliable techniques which can be helpful in critically examining the complexities involved in brain activities of AD patients and its association with other pathological and physical changes in the patients. This paper concludes by proposing an objective-wise methodological structure for biostatistical analyses of AD.

show abstract

“…In one report, the ratio of free- to cell-bound Aβ 1-17 in blood discriminated between healthy individuals and individuals with MCI or mild AD with high sensitivity and specificity [7]. Other novel Aβ isoforms may also be useful for monitoring the biochemical effect of treatment.…”

Section: Blood Based Markers Of Amyloid Pathophysiologymentioning

confidence: 99%

Developing novel blood‐based biomarkers for Alzheimer's disease

Snyder

Carrillo

Grodstein

et al. 2014

Alzheimer's & Dementia

145

115

View full text Add to dashboard Cite

Alzheimer's disease is the public health crisis of the 21st century. There is a clear need for a widely available, inexpensive and reliable method to diagnosis Alzheimer's disease in the earliest stages, track disease progression, and accelerate clinical development of new therapeutics. One avenue of research being explored is blood based biomarkers. In April 2012, the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation convened top scientists from around the world to discuss the state of blood based biomarker development. This manuscript summarizes the meeting and the resultant discussion, including potential next steps to move this area of research forward.

show abstract

O2‐03‐05: Beta‐amyloid‐17 is a major beta‐amyloid fragment isoform in cerebrospinal fluid and blood that shows diagnostic value

Cited by 10 publications

References 0 publications

Alzheimer’s Disease: Biomarkers And Future Targets For Drug Intervention

Alzheimer’s Disease: Biomarkers And Future Targets For Drug Intervention

Untitled

Developing novel blood‐based biomarkers for Alzheimer's disease

Contact Info

Product

Resources

About